Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daito Pharmaceutical CoTSE:4577 -0.22%83 EV-to-EBIT is 11.16 as of Aug. 25, 2026, which is 19% above its 10-year median of 9.34. GuruFocus rates TSE:4577 with a GF Score™ of 83/100 and a GF Value™ of 円1,284.15 (Fairly Valued). The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Daito Pharmaceutical Co ranks better than 65.07% on this metric.
Daito Pharmaceutical Co (TSE:4577) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Daito Pharmaceutical Co's Enterprise Value for the quarter that ended in Feb. 2026 was 円51,224 Mil.
Daito Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daito Pharmaceutical Co EV-to-EBIT Related Terms
Daito Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's EV-to-EBIT falls into.
Daito Pharmaceutical Co's current Enterprise Value is 円46,819 Mil.
Daito Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daito Pharmaceutical Co (TSE:4577) has a EV-to-EBIT of 11.16 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daito Pharmaceutical Co and its competitors. This is 19% above median its historical median of 9.34. Over the past decade, Daito Pharmaceutical Co's EV-to-EBIT has ranged from 5.39 to 17.82. According to the industry distribution chart, Daito Pharmaceutical Co ranks #241 out of 690 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Daito Pharmaceutical Co's EV-to-EBIT too high?
Daito Pharmaceutical Co's current EV-to-EBIT of 11.16 is 19% above median its 10-year median of 9.34. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 17.82. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Daito Pharmaceutical Co's value of 11.16 is 29.4% below this industry median. Based on the distribution chart, Daito Pharmaceutical Co ranks #241 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daito Pharmaceutical Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #241 out of 690 companies for EV-to-EBIT. This puts Daito Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.81. Daito Pharmaceutical Co's value of 11.16 is 29.4% below this benchmark. Historically, Daito Pharmaceutical Co's own EV-to-EBIT has ranged from 5.39 to 17.82 over the past decade. While the company's 10-year median is 9.34 vs. the industry median of 15.81, Daito Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daito Pharmaceutical Co's current EV-to-EBIT of 11.16 is 29.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current EV-to-EBIT is 11.16, which is 19% above median its own 10-year median of 9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,284.15, compared to a current price of 円1,360.00 — trading 5.9% above its estimated fair value. The current EV-to-EBIT is 11.16, which is 19% above median its 10-year median of 9.34 and 29.4% below the Drug Manufacturers industry median of 15.81. Daito Pharmaceutical Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current EV-to-EBIT is 11.16 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円1,360.00 is trading 5.9% above its estimated GF Value™ of 円1,284.15.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
EV-to-EBIT: 11.16 (19% above median its 10-year median of 9.34)
GF Value™: 円1,284.15 vs. price of 円1,360.00 (5.9% above fair value)
Industry Position: 29.4% below the Drug Manufacturers median (#241 of 690)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
